Skip to content

Keratinocyte CCL2 release assay

Primary human keratinocytes (skin cells) are stimulated with a cytokine cocktail containing IL-4, IL-13, IL-22 & IFN-gamma, to induce an eczema-relevant response, detected as an increase in CCL2 release. Your compound is tested for the ability to inhibit the inflammatory response, measured as an inhibition of CCL2 release. Cell viability is also assessed, as a measure of general compound cytotoxicity.

Download the assay protocol.

The Keratinocyte CCL2 release assay process

The assay utilizes primary human keratinocytes seeded in a 384-well microtiter plate and stimulated with the cytokine cocktail IL-4, IL-13, IL-22 and IFNg to induce increased secretion of the proinflammatory cytokine CCL2. The test molecule, dissolved in DMSO, is added in different concentrations and after 72 hours the CCL2 leves, as well as the cell viability is measured as the final end point.

Scroll to top